default author photo

Alejandro Martín-Quirós

La Paz University Hospital - Emergency Department and Emergent Pathology Research Group

Spain

SCHOLARLY PAPERS

2

DOWNLOADS

93

TOTAL CITATIONS

1

Scholarly Papers (2)

1.

Cellular and Humoral Functional Responses After BNT162b2 SARS-CoV-2 mRNA Vaccination Differ Between Naïve and COVID-19-Recovered Individuals

Number of pages: 44 Posted: 07 Jul 2021
Hospital Universitario La Paz - The Innate Immune Response Group, La Paz University Hospital - The Innate Immune Response Group, La Paz University Hospital - The Innate Immune Response Group, La Paz University Hospital - Emergency Department and Emergent Pathology Research Group, La Paz University Hospital - The Innate Immune Response Group, Hospital Universitario La Paz - The Innate Immune Response Group, La Paz University Hospital - The Innate Immune Response Group, La Paz University Hospital - The Innate Immune Response Group, Carlos III Institute of Health - AIDS Immunopathogenesis Unit, Carlos III Institute of Health - CIBER de Epidemiología y Salud Pública (CIBERESP), Universidad Carlos III de Madrid - AIDS Immunopathogenesis Unit, La Paz University Hospital - Emergency Department and Emergent Pathology Research Group, Hospital Universitario La Paz - The Innate Immune Response Group, La Paz University Hospital - Emergency Department and Emergent Pathology Research Group, La Paz University Hospital - Emergency Department and Emergent Pathology Research Group, La Paz University Hospital - Emergency Department and Emergent Pathology Research Group, Eurofins-Ingenasa, Eurofins-Ingenasa, La Paz University Hospital - The Innate Immune Response Group, La Paz University Hospital - The Innate Immune Response Group, La Paz University Hospital - The Innate Immune Response Group and Hospital Universitario La Paz - Immunomodulation Laboratory
Downloads 61 (951,658)
Citation 1

Abstract:

Loading...

SARS-CoV-2, BNT162b2 vaccine, COVID-19-recovered, cellular responses

2.

A Phase I, Dose-Escalation Clinical Trial to Evaluate the Safety of Infusing Natural Killer Cells as Adoptive Therapy in COVID-19: Release

Number of pages: 26 Posted: 14 Jun 2024
Hospital Universitario La Paz, Universidad de Alicante - Alicante’s Institute for Health and Biomedical Research (ISABIAL), University of the Basque Country - Biocruces Bizkaia Health Research Institute, Health Research Institute Hospital La Fe, Icahn School of Medicine at Mount Sinai - Precision Immunology Institute, Mount Sinai Health System - Icahn School of Medicine, Icahn School of Medicine at Mount Sinai - Precision Immunology Institute, Hospital Universitario La Paz, La Paz University Hospital - Emergency Department and Emergent Pathology Research Group, Centro de Transfusión de la Comunidad de Madrid, University of the Basque Country - Biocruces Bizkaia Health Research Institute, University of the Basque Country - Biocruces Bizkaia Health Research Institute, University of the Basque Country - Biocruces Bizkaia Health Research Institute, Hospital Universitario La Paz - Servicio de Farmacología Clínica, La Paz Institute for Health Research (IdiPAZ), Centro de Transfusión de la Comunidad de Madrid, Centro de Transfusión de la Comunidad de Madrid, La Paz Institute for Health Research (IdiPAZ), Hospital Universitario La Paz, Miguel Hernández University of Elche - Pediatric Hemato-oncology Department, University of the Basque Country - Biocruces Bizkaia Health Research Institute and Hospital Universitario La Paz
Downloads 32 (1,290,922)

Abstract:

Loading...

Cell therapyNatural Killer cellsmicrochimerimsSARS-CoV-2COVID-19Convalescent donorCytokines